NSCLC patients displayed heterogeneous IL-2 kinetics, with some showing high baseline levels that declined over time and others maintaining low levels throughout coinciding with existing studies that report an imbalance of the IL-2/IL-2 receptor system [35] in advanced NSCLC and its association with disease activity and progression [36,37,38]. Here, IL2 is linked to non-small cell lung carcinoma.